Marci Troxell, DO
Neurology · Anchorage, AKNPI 1578701033
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Biogen at 41.2% of the total. Reporting peaked in 2024 at $295 and has fallen 91.9% since, to $24 in 2025. That places this record below the midpoint for neurology clinicians in AK, where the typical reported total is $2,594.
Across 12 payments — averaging $49.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$245
- Argenx US, Inc.$90
- SK Life Science, Inc.$85
- Livanova USA, Inc.$42
- Genentech USA, Inc.$38
- Tanabe Pharma America, Inc.$28
- plus $65 from 3 others
What the payments were for
- Food & beverage$55293%
- Education$427%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 3 | $245 |
| Argenx US, Inc. | 1 | $90 |
| SK Life Science, Inc. | 1 | $85 |
| Livanova USA, Inc. | 1 | $42 |
| Genentech USA, Inc. | 2 | $38 |
| Tanabe Pharma America, Inc. | 1 | $28 |
| TG Therapeutics, Inc. | 1 | $28 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $24 |
| EMD Serono, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPINRAZA$125
How this compares
$593 in reported general payments places this provider in the 25th percentile of 21 neurology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 24 | $203,008 |
| Radicava OrsEdaravone | 12 | $174,179 |
| Nurtec OdtRimegepant Sulfate | 37 | $54,038 |
| Dimethyl Fumarate | 11 | $45,311 |
| GlatopaGlatiramer Acetate | 14 | $24,135 |
| Aimovig AutoinjectorErenumab-Aooe | 27 | $20,066 |
| UbrelvyUbrogepant | 15 | $14,921 |
| Dalfampridine ErDalfampridine | 18 | $14,814 |
| Lacosamide | 23 | $12,109 |
| Levetiracetam | 100 | $5,234 |
| Mycophenolate Mofetil | 28 | $3,614 |
| Pyridostigmine Bromide | 40 | $3,469 |
| Gabapentin | 99 | $2,513 |
| Divalproex Sodium | 39 | $1,954 |
| Memantine Hcl | 53 | $1,923 |
Paid to pharmacies, not to this prescriber.
Other neurology in Anchorage
- Stanford DownsAnchorage$19K
- Mary DownsAnchorage$17K
- Scot HinesAnchorage$8K
- David HenzlerAnchorage$6K
- Aaron TauerAnchorage$3K
- Franklin EllensonAnchorage$2K
- Thomas KennedyAnchorage$1K
- Robert LadaAnchorage$275
- Kim MaddenAnchorage$15
- Lawrence JedlickaAnchorage$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.